Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Amgen K-A, Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units, indicating that the company's technical innovations are being evaluated across different specialized groups. The portfolio involves 2 distinct examiners, meaning that each pending action is being reviewed by a different official with potentially different examination criteria.
BRISTOL, LYNN ANNE is the busiest examiner for this company, currently handling 1 pending office action. While she is one of the 2 distinct examiners involved, her work represents a portion of the company's current active prosecution. The distribution of 2 pending office actions across 2 distinct art units suggests that Amgen K-A, Inc. must adapt its legal arguments to suit the specific technical requirements of each unit. With distinct examiners overseeing the pending office actions, the company should ensure that its prosecution strategy remains consistent across the Biotechnology & Pharmaceuticals field. This dual-track prosecution requires careful management to achieve favorable outcomes in both distinct art units, starting with the 1 pending action under the busiest examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| JIANG, DONG | 1 | 44.4% | +54.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18045534 | METHOD OF TREATING DISEASES USING AN IL-17 RECEPTOR ANTIBODY FORMULATION | JIANG, DONG | 36d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18045534 | METHOD OF TREATING DISEASES USING AN IL-17 RECEPTOR ANTIBODY FORMULATION | JIANG, DONG | 36d overdue |
| 18530387 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18530387 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | BRISTOL, LYNN ANNE | 1643 | §112DP | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18045534 | METHOD OF TREATING DISEASES USING AN IL-17 RECEPTOR ANTIBODY FORMULATION | JIANG, DONG | 1674 | §103§112Other | Non-Final OA | 36d overdue | Pending | Oct 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial